Artivion Inc (AORT)vsEdwards Lifesciences Corp (EW)
AORT
Artivion Inc
$26.17
-2.71%
HEALTHCARE · Cap: $1.30B
EW
Edwards Lifesciences Corp
$88.97
-0.70%
HEALTHCARE · Cap: $49.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 1320% more annual revenue ($6.51B vs $458.69M). EW leads profitability with a 15.4% profit margin vs 2.5%. EW appears more attractively valued with a PEG of 2.09. EW earns a higher WallStSmart Score of 55/100 (C).
AORT
Hold41
out of 100
Grade: D
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-32.5%
Fair Value
$30.26
Current Price
$26.17
$4.09 premium
Margin of Safety
+69.3%
Fair Value
$257.97
Current Price
$88.97
$169.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
17.5% revenue growth
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.6% — below average capital efficiency
2.5% margin — thin
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : AORT
The strongest argument for AORT centers on Price/Book, Revenue Growth. Revenue growth of 17.5% demonstrates continued momentum.
Bull Case : EW
The strongest argument for EW centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : AORT
The primary concerns for AORT are EPS Growth, Market Cap, Return on Equity. A P/E of 107.3x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.2x leaves little room for execution misses.
Key Dynamics to Monitor
AORT profiles as a growth stock while EW is a mature play — different risk/reward profiles.
AORT carries more volatility with a beta of 1.25 — expect wider price swings.
AORT is growing revenue faster at 17.5% — sustainability is the question.
AORT generates stronger free cash flow (-7M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 41/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Artivion Inc
HEALTHCARE · MEDICAL DEVICES · USA
Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?